Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix - Full Text View - ClinicalTrials.gov
  personal physician (100)
    For additional information regarding investigative sites for this trial,
contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9
AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal
physician.
  speak (100)
    For additional information regarding investigative sites for this trial,
contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9
AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal
physician.
  UTC/GMT (100)
    For additional information regarding investigative sites for this trial,
contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9
AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal
physician.
  Eastern Time (100)
    For additional information regarding investigative sites for this trial,
contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9
AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal
physician.
  investigative sites (100)
    For additional information regarding investigative sites for this trial,
contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9
AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal
physician.
  cisplatin (85)
    Half the patients will receive gemcitabine plus cisplatin while undergoing
radiation therapy, followed by adjuvant gemcitabine and cisplatin and the
other half will receive cisplatin along with radiation therapy without
adjuvant therapy.
    Phase III, open-label, randomized study comparing concurrent gemcitabine
plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin
versus concurrent cisplatin and radiation in patients with stage IIB to
IVA carcinoma of the cervix.
  radiation (57)
    Half the patients will receive gemcitabine plus cisplatin while undergoing
radiation therapy, followed by adjuvant gemcitabine and cisplatin and the
other half will receive cisplatin along with radiation therapy without
adjuvant therapy.
    Phase III, open-label, randomized study comparing concurrent gemcitabine
plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin
versus concurrent cisplatin and radiation in patients with stage IIB to
IVA carcinoma of the cervix.
  gemcitabine (57)
    Half the patients will receive gemcitabine plus cisplatin while undergoing
radiation therapy, followed by adjuvant gemcitabine and cisplatin and the
other half will receive cisplatin along with radiation therapy without
adjuvant therapy.
    Phase III, open-label, randomized study comparing concurrent gemcitabine
plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin
versus concurrent cisplatin and radiation in patients with stage IIB to
IVA carcinoma of the cervix.
  adjuvant gemcitabine (42)
    Half the patients will receive gemcitabine plus cisplatin while undergoing
radiation therapy, followed by adjuvant gemcitabine and cisplatin and the
other half will receive cisplatin along with radiation therapy without
adjuvant therapy.
    Phase III, open-label, randomized study comparing concurrent gemcitabine
plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin
versus concurrent cisplatin and radiation in patients with stage IIB to
IVA carcinoma of the cervix.
  radiation therapy (42)
    Half the patients will receive gemcitabine plus cisplatin while undergoing
radiation therapy, followed by adjuvant gemcitabine and cisplatin and the
other half will receive cisplatin along with radiation therapy without
adjuvant therapy.
  Full Summary
    Half the patients will receive gemcitabine plus cisplatin while undergoing
radiation therapy, followed by adjuvant gemcitabine and cisplatin and the
other half will receive cisplatin along with radiation therapy without
adjuvant therapy.
    For additional information regarding investigative sites for this trial,
contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9
AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal
physician.
    Phase III, open-label, randomized study comparing concurrent gemcitabine
plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin
versus concurrent cisplatin and radiation in patients with stage IIB to
IVA carcinoma of the cervix.
  Short Summary
    Half the patients will receive gemcitabine plus cisplatin while undergoing
radiation therapy, followed by adjuvant gemcitabine and cisplatin and the
other half will receive cisplatin along with radiation therapy without
adjuvant therapy.
    Phase III, open-label, randomized study comparing concurrent gemcitabine
plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin
versus concurrent cisplatin and radiation in patients with stage IIB to
IVA carcinoma of the cervix.
    For additional information regarding investigative sites for this trial,
contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9
AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal
physician.
  Map created automatically by
WebSummarizer
product of Context Discovery
http://www.contextdiscovery.com
websummarizer@contextdiscovery.com